Back to search results

FAPI PET for Fibrotic Lung Disease

This study is looking into how a radioactive substance called FAPI tracer can help us better understand and track fibrotic lung disease (scarring in the lungs). Researchers will use FAPI tracer along with PET/MRI (positron emission tomography/magnetic resonance imaging) scans to see how FAPI binds to certain cells in the lungs. This could help doctors diagnose and monitor the disease more effectively. You may be able to join if you are 18 or older and have fibrotic hypersensitivity pneumonitis (HSP) or idiopathic pulmonary fibrosis, especially if you are starting a new treatment or changing your current one. The main goal is to see how FAPI uptake changes over 6 months. The current recruitment status is unclear, and the study plans to enroll 50 participants.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It aims to enroll 50 participants.
What's involved
Participants will undergo up to 4 PET/MRI scans, which involve an injection of FAPI tracer. The primary endpoint is measured at Baseline to 6 months.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures changes in FAPI uptake from the start of the study to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06940427

Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis

Recruiting
PHASE2Ages 18+InterventionalDiagnostic
University of Wisconsin, Madison
~50 participants
Updated 2026-03-11 on ClinicalTrials.gov
What's tested:FAPI tracerPET/MRI

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in FAPI uptake
Measured over Baseline to 6 months

Conditions

Fibrosis Lung

Explore related trials

Extrinsic Allergic AlveolitisIdiopathic Pulmonary Fibrosis

NCT06940427

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Wisconsin - Madison

    Madison, Wisconsinstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ali Pirasteh, MD · PRINCIPAL_INVESTIGATOR · University of Wisconsin, Madison

Who to contact

Radiology Studies
[email protected]
608-282-8349
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older
Able and willing to provide informed consent
Group A: Clinically evaluated for need for initiation of new treatment (in patients not on current treatment), initiation of change in current treatment, or addition of new treatment (to any current treatment) in the setting of fibrotic hypersensitivity pneumonitis (HSP) or idiopathic pulmonary fibrosis (IPF), per standard of clinical care at UW Health.
Group B: Clinically evaluated and stable without need for initiation of new treatment (in patients not on current treatment), initiation of change in current treatment, nor addition of new treatment (to any current treatment) in the setting of fibrotic hypersensitivity pneu-monitis (HSP) or idiopathic pulmonary fibrosis (IPF), per standard of clinical care at UW Health.
Crossover (Group B to A): Enrolled in Group B and found at next SOC clinical follow up to have need for initiation of new treatment (in patients not on current treatment), initiation of change in current treatment, or addition of new treatment (to any current treatment) in the setting of fibrotic hypersensitivity pneumonitis (HSP) or idiopathic pulmonary fibrosis (IPF), per standard of clinical care at UW Health.
Willing and able to undergo PET/MRI.
Participants requiring intravenous (IV) conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:
The subject has their own prescription for the medication
Informed consent is obtained prior to the self-administration of this medication
They come to the research visit with a driver

Exclusion

Participant is unable or unwilling to provide informed consent
Participant is pregnant
Participant with contraindication(s) to or inability to undergo PET/MRI
Participants with contraindications to GBCA will be asked to undergo research imaging without the use of contrast. Contraindications may be severe kidney disease or previously documented GFR \< 30 ml/min/1.73 m2

What this trial measures

  • Change in FAPI uptakeBaseline to 6 months

    FAPI uptake of fibrotic lesions as measured by Standardized Uptake Value (SUV). SUV quantifies the tracer uptake, helping to differentiate between normal and abnormal tissues and assess the extent of tumor activity.